I am a
Home I AM A Search Login

Papers of the Week

Papers: 3 Dec 2022 - 9 Dec 2022

2022 Dec 02

J Headache Pain



Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.


Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen C L, Josiassen M K, Phul R, Sperling B
J Headache Pain. 2022 Dec 02; 23(1):153.
PMID: 36460983.


The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the placebo-controlled portion, eptinezumab relative to placebo demonstrated greater reductions in migraine and headache frequency, migraine and headache severity, and acute medication use. The objective of this report is to describe the effects of eptinezumab on self-reported work productivity in the placebo-controlled portion of DELIVER.